BBCMF (Lir Life Sciences) Return-on-Tangible-Asset: -674.61% (As of Jan. 2026)


BBCMF Lir Life Sciences Corp BBCMF
15 GF Score
Price $0.05
View Full Analysis

What is Lir Life Sciences Return-on-Tangible-Asset?

Lir Life Sciences BBCMF 15 Return-on-Tangible-Asset is -674.61% as of Jan. 2026. GuruFocus rates BBCMF with a GF Score™ of 15/100. Among 1,418 Biotechnology companies, Lir Life Sciences ranks worse than 95.98% on this metric.

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Lir Life Sciences's annualized Net Income for the quarter that ended in Jan. 2026 was $-6.28 Mil. Lir Life Sciences's average total tangible assets for the quarter that ended in Jan. 2026 was $0.93 Mil. Therefore, Lir Life Sciences's annualized Return-on-Tangible-Asset for the quarter that ended in Jan. 2026 was -674.61%.

The historical rank and industry rank for Lir Life Sciences's Return-on-Tangible-Asset or its related term are showing as below:

BBCMF' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -379.89   Med: -260.12   Max: -260.12
Current: -379.89

During the past 2 years, Lir Life Sciences's highest Return-on-Tangible-Asset was -260.12%. The lowest was -379.89%. And the median was -260.12%.

BBCMF's Return-on-Tangible-Asset is ranked worse than
95.98% of 1418 companies
in the Biotechnology industry
Industry Median: -35.915 vs BBCMF: -379.89

Lir Life Sciences  (OTCPK:BBCMF) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Lir Life Sciences Return-on-Tangible-Asset Related Terms


Lir Life Sciences Return-on-Tangible-Asset Historical Data

* Premium members only.

The historical data trend for Lir Life Sciences's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lir Life Sciences Return-on-Tangible-Asset Chart

Lir Life Sciences Annual Data
Trend Apr24 Apr25
Return-on-Tangible-Asset
0.00 -255.70

Lir Life Sciences Quarterly Data
Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Return-on-Tangible-Asset Get a 7-Day Free Trial 0.00 -721.84 -832.65 -32.92 -674.61

BBCMF vs VRTX, REGN, ALNY: Return-on-Tangible-Asset Comparison

For the Biotechnology subindustry, Lir Life Sciences's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lir Life Sciences Return-on-Tangible-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lir Life Sciences's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Lir Life Sciences's Return-on-Tangible-Asset falls into.


BBCMF
15GF Score
Lir Life Sciences Corp BBCMF
Return-on-Tangible-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lir Life Sciences Return-on-Tangible-Asset Calculation

Lir Life Sciences's annualized Return-on-Tangible-Asset for the fiscal year that ended in Apr. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Apr. 2025 )  (A: Apr. 2024 )(A: Apr. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Apr. 2025 )  (A: Apr. 2024 )(A: Apr. 2025 )
=-0.303/( (0.15+0.087)/ 2 )
=-0.303/0.1185
=-255.70 %

Lir Life Sciences's annualized Return-on-Tangible-Asset for the quarter that ended in Jan. 2026 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Jan. 2026 )  (Q: Oct. 2025 )(Q: Jan. 2026 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Jan. 2026 )  (Q: Oct. 2025 )(Q: Jan. 2026 )
=-6.284/( (1.107+0.756)/ 2 )
=-6.284/0.9315
=-674.61 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Jan. 2026) net income data.

What does a Return-on-Tangible-Asset of -674.61% mean?
Lir Life Sciences (BBCMF) has a Return-on-Tangible-Asset of -674.61% as of Jan. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Lir Life Sciences and its competitors. According to the industry distribution chart, Lir Life Sciences ranks #1361 out of 1418 companies in the Biotechnology industry, placing it in the top 96%.
Is Lir Life Sciences' Return-on-Tangible-Asset too high?
Lir Life Sciences' current Return-on-Tangible-Asset is -674.61%. Based on the distribution chart, Lir Life Sciences ranks #1361 out of 1418 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lir Life Sciences has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Lir Life Sciences' Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lir Life Sciences ranks #1361 out of 1418 companies for Return-on-Tangible-Asset. This places Lir Life Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Lir Life Sciences and its competitors. Lir Life Sciences's current Return-on-Tangible-Asset is -674.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lir Life Sciences stock overvalued right now?
Lir Life Sciences (BBCMF) has a current Return-on-Tangible-Asset of -674.61%. The current Return-on-Tangible-Asset is -674.61%. Lir Life Sciences' overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Lir Life Sciences (BBCMF), the current Return-on-Tangible-Asset is -674.61% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lir Life Sciences Business Description

Other Exchanges N790:GermanySKNY:Canada
Address 505-1505 West 2nd Avenue, Vancouver, BC, CAN, V6J 1H2
Lir Life Sciences Corp is a biotechnology company developing transdermal and sublingual drug-delivery technologies for GLP-1-based obesity therapies, with the focus of improving accessibility and patient experience.
15GF Score

Get the complete analysis for BBCMF

Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.05
Price